Details

Autor(en) / Beteiligte

• GAWROŃSKA, A.
• DZIECHCIARZ, P.
• HORVATH, A.
• SZAJEWSKA, H.

Titel

A randomized double‐blind placebo‐controlled trial of Lactobacillus GG for abdominal pain disorders in children

Ist Teil von

• Alimentary pharmacology & therapeutics, 2007-01, Vol.25 (2), p.177-184

Ort / Verlag

Oxford, UK: Blackwell Publishing Ltd

Erscheinungsjahr

2007

Quelle

Access via Wiley Online Library

Beschreibungen/Notizen

• Summary Background Functional abdominal pain disorders (FAPD) are common in school‐aged children; however, there is no reliable treatment. Aim To determine the efficacy of Lactobacillus rhamnosus GG (LGG) for treating FAPD in children. Methods A total of 104 children who fulfilled the Rome II criteria for functional dyspepsia (FD), or irritable bowel syndrome (IBS), or functional abdominal pain (FAP) were enrolled in a double‐blind, randomized controlled trial in which they received LGG (n = 52), or placebo (n = 52) for 4 weeks. Results For the overall study population, those in the LGG group were more likely to have treatment success (no pain) than those in the placebo group (25% vs. 9.6%, relative benefit (RB) 2.6, 95% confidence interval (CI): 1.05–6.6, number needed to treat (NNT) 7, 95% CI: 4–123). For children with IBS (n = 37), those in the LGG group were more likely to have treatment success than those in the placebo group (33% vs. 5%, RB 6.3, 95% CI: 1.2–38, NNT 4, 95% CI: 2–36) and reduced frequency of pain (P = 0.02), but not pain severity (P = 0.10). For the FD group (n = 20) and FAP group (n = 47), no differences were found. Conclusion The LGG appears to moderately increase treatment success, particularly among children with IBS.